Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma

As CD20 has become an established target for treating B‐cell malignancies, there is interest in developing anti‐CD20 antibodies with different functional activity from rituximab that might translate into improved efficacy. Obinutuzumab (GA101) is a glycoengineered, humanized type II anti‐CD20 monocl...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Uchida, Toshiki, Suzuki, Tatsuya, Kobayashi, Yukio, Mori, Masakazu, Terui, Yasuhito, Yokoyama, Masahiro, Hotta, Tomomitsu
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2012
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657177/
https://ncbi.nlm.nih.gov/pubmed/23046388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12040
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi